3-methyl-2,3-dihydrobenzofuran-3-ol | 88112-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 3-methyl-2,3-dihydrobenzofuran-3-ol
• 英文别名: 3-methyl-2H-1-benzofuran-3-ol
• CAS: 88112-02-1
• 化学式: C₉H₁₀O₂
• 分子量: 150.177
• InChiKey: WBVQDYOZNNSTQY-UHFFFAOYSA-N

物化性质

• 熔点：
  48-49 °C
• 沸点：
  265.9±29.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (2-乙酰基苯氧基)乙酸 以 乙腈 为溶剂， 反应 2.0h， 以38%的产率得到3-methyl-2,3-dihydrobenzofuran-3-ol
  参考文献：
  名称：

  Horaguchi, Takaaki; Tsukada, Chikara; Hasegawa, Eietsu, Journal of Heterocyclic Chemistry, 1991, vol. 28, # 5, p. 1261 - 1272

  摘要：

  DOI：

文献信息

• Development and Mechanistic Study of Quinoline-Directed Acyl C–O Bond Activation and Alkene Oxyacylation Reactions
  作者：Giang T. Hoang、Dylan J. Walsh、Kathryn A. McGarry、Constance B. Anderson、Christopher J. Douglas

  DOI：10.1021/acs.joc.6b03011

  日期：2017.3.17

  acyl substituent across an alkene, oxyacylation of alkenes, using rhodium catalyzed C–O bond activation of an 8-quinolinyl ester is described. Our unsuccessful attempts at intramolecular carboacylation of ketones via C–C bond activation ultimately informed our choice to pursue and develop the intramolecular oxyacylation of alkenes via quinoline-directed C–O bond activation. We provide a full account

  描述了使用铑催化的8-喹啉基酯的羰基化作用，在烯烃上进行烷氧基和酰基取代基的分子内加成，烯烃的氧酰化。我们通过C-C键活化进行酮类分子内碳酰化的失败尝试最终使我们选择了通过喹啉定向的C-O键活化来追求和发展烯烃的分子内氧酰化。我们全面介绍了我们的催化剂发现，底物范围以及喹啉导向的烯烃氧酰化反应的机理实验。
• [EN] DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS<br/>[FR] INHIBITEURS DOUBLES DE NAV1.2/5HT2A POUR TRAITER DES TROUBLES DU SNC
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2018026371A1

  公开（公告）日：2018-02-08

  Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  公开了化学式I的化合物，以及含有这些化合物的药物组合物。还公开了治疗患有神经系统或精神障碍的患者的方法。这些障碍包括抑郁症、躁郁症、疼痛、精神分裂症、强迫症、成瘾、社交障碍、注意力缺陷多动障碍、焦虑障碍、自闭症、认知障碍，或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及在神经系统疾病如阿尔茨海默病和帕金森病中的睡眠障碍。
• Palladium(II)-catalyzed intramolecular addition of arylboronic acids to ketones
  作者：Guixia Liu、Xiyan Lu

  DOI：10.1016/j.tet.2008.05.056

  日期：2008.7

  A palladium(II)-catalyzed intramolecular addition of arylboronic acids to ketones was developed. Compared to Pd(OAc)2 catalysis system, cationic palladium complex with dppp as the ligand has higher catalytic activity and efficiency for wider scope of substrates. From this reaction, the normal addition product or the dehydrated product could be selectively furnished as controlled by additives. Highly

  开发了钯（II）催化的芳基硼酸分子内加成酮。与Pd（OAc）2催化体系相比，以dppp为配体的阳离子钯配合物具有更高的催化活性和效率，可用于更广泛的底物范围。通过该反应，可以根据添加剂的控制选择性地提供正常的加成产物或脱水产物。通过使用手性阳离子钯络合物作为催化剂，可以获得高旋光性的环状叔醇（至多96％ee）。
• Cationic Palladium Complex Catalyzed Highly Enantioselective Intramolecular Addition of Arylboronic Acids to Ketones. A Convenient Synthesis of Optically Active Cycloalkanols
  作者：Guixia Liu、Xiyan Lu

  DOI：10.1021/ja0672425

  日期：2006.12.1

  An efficient and convenient synthesis of optically active cycloalkanols by utilizing the chiral cationic palladium complex as the catalyst was achieved in mild conditions with high yield and high enantioselectivity.

  以手性阳离子钯配合物为催化剂，在温和的条件下，以高收率和高对映选择性实现了高效、方便地合成光学活性环烷醇。
• Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US11186564B2

  公开（公告）日：2021-11-30

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  式 I 的化合物： 以及含有此类化合物的药物组合物。还公开了治疗有需要的患者的神经或精神障碍的方法。此类疾病包括抑郁症、双相情感障碍、疼痛、精神分裂症、强迫症、成瘾症、社交障碍、注意力缺陷多动障碍、焦虑症、自闭症、认知障碍或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及神经系统疾病如阿尔茨海默病和帕金森病的睡眠障碍。